U.S. Antacids Market Will Grow Rapidly In Coming Years

U.S. Antacids Market Summary

The U.S. antacids market size was estimated at USD 3.00 billion in 2024 and is projected to reach USD 3.73 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.7% from 2025 to 2030. One of the primary factors driving this market growth is the shift in dietary habits across the U.S. population, including increased consumption of processed foods, caffeinated beverages, and spicy meals, all of which can trigger acidity and indigestion. These changing patterns are contributing to the rising demand for quick-relief products like antacids.

An increasing prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), peptic ulcers, and general stomach discomfort, is also playing a crucial role in boosting the market. These conditions often result in symptoms like heartburn, acid reflux, and indigestion, prompting individuals to seek fast-acting remedies. According to a report released by the Centers for Disease Control and Prevention (CDC) in December 2024, approximately 5.9% of adults in the United States were diagnosed with ulcers. In addition to these health factors, growing public awareness regarding digestive health and the widespread availability of over-the-counter (OTC) medications make antacids easily accessible, further contributing to the market’s steady growth.

Key Market Trends & Insights

• Among product types, the liquid antacids segment accounted for a significant share of 31.3% in 2024. The preference for liquid formulations stems from their faster onset of action, ease of ingestion, and suitability for specific groups such as children, elderly individuals, and patients with difficulty swallowing tablets or capsules. These characteristics make liquid antacids a favored choice in both clinical and home-use settings.
• In terms of distribution channels, retail pharmacies held a prominent share of the market in 2024. This is due to their widespread presence in high-traffic areas such as malls, residential neighborhoods, and shopping centers, which offer consumers easy and quick access to antacid products without the need for prescriptions. The growing preference for self-medication and convenience is helping this segment maintain its leading position.
• The hospital pharmacy segment is expected to register a notable growth rate throughout the forecast period. The rise in hospital admissions related to gastrointestinal issues like GERD, acid reflux, and peptic ulcers is fueling demand for antacids in clinical settings. Additionally, physicians frequently recommend antacids for inpatients as part of broader treatment plans for digestive disorders, thereby supporting the segment’s expansion.

Order a free sample PDF of the U.S. Antacids Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 3.00 billion
• 2030 Projected Market Size: USD 3.73 billion
• CAGR (2025 - 2030): 3.7%

Key Companies & Market Share Insights

The competitive landscape of the U.S. antacids market consists of numerous multinational corporations as well as smaller domestic players, all aiming to expand their market share through a variety of strategies. These include the launch of new product formulations, expansion into new regional markets, and forming strategic alliances or joint ventures to strengthen their distribution and research capabilities.

Haleon Group of Companies currently holds a leading position in the U.S. digestive health market, supported by its strong antacid brands such as Tums and ENO. Tums is a well-known chewable calcium carbonate-based antacid known for its rapid relief from heartburn, while ENO, an effervescent powder formulation, offers quick neutralization of stomach acid, making both brands popular choices among consumers.

Pfizer Inc., a major player in the broader U.S. pharmaceutical market, also maintains a strong presence in the antacids segment. The company’s product Nexium 24HR, an OTC solution for heartburn relief, benefits from strong brand recognition and wide-scale retail distribution across pharmacies and supermarkets. Pfizer's robust marketing and retail strategy help reinforce its position in the competitive antacid market landscape.

Key Players

• Haleon Group of Companies.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr. Reddy’s Laboratories Ltd.
• Sanofi
• Reckitt Benckiser Group plc
• Sun Pharmaceuticals Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Procter & Gamble

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

In conclusion, the U.S. antacids market continues to show consistent growth due to changing dietary trends, rising digestive disorders, and increasing consumer preference for readily accessible OTC solutions. Liquid formulations and retail pharmacy channels are contributing significantly to market momentum, while hospital pharmacies are expected to grow due to increased clinical demand. Key players like Haleon and Pfizer are driving innovation and market expansion through trusted brands and strategic initiatives. As awareness about gastrointestinal health rises and self-medication becomes more common, the antacids market is likely to remain an essential segment of the U.S. healthcare landscape through 2030 and beyond.